<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00826202</url>
  </required_header>
  <id_info>
    <org_study_id>08I/C33</org_study_id>
    <secondary_id>CDDG 1 U01 MH074356-01</secondary_id>
    <nct_id>NCT00826202</nct_id>
  </id_info>
  <brief_title>D-serine for the Schizophrenia Prodrome</brief_title>
  <official_title>D-Serine vs Placebo for the Schizophrenia Prodrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nathan Kline Institute for Psychiatric Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Zucker Hillside Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Nathan Kline Institute for Psychiatric Research</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine the safety and efficacy of D-serine as an early
      intervention treatment for the schizophrenia prodrome condition. This study is a
      placebo-controlled trial of D-serine in the symptomatic treatment of patients with the
      schizophrenia prodrome. Seventy two subjects meeting criteria for the schizophrenia prodrome
      will be included in this study, 24 at each site (Yale, Nathan Kline Institute and Zucker
      Hillside Hospital). The primary outcome measures will include symptom and neuropsychological
      measures. The duration of this study is two and a half years.

      This research with D-serine holds out the prospect of direct benefit for the patient's
      current symptoms. Subjects may also benefit from the close monitoring of their symptoms, so
      that, if schizophrenic psychosis does occur, the psychosis will be recognized and treatment
      may begin with minimal delay. This study also could be of benefit by suggesting a promising
      lead in early intervention in the schizophrenic prodrome.

      Overall Design Summary. We propose for prodromal patients to be randomized to D-serine vs
      placebo for 16 weeks. To insure that all subjects have the opportunity to receive D-serine,
      there will be an optional 16 week cross-over trial on the alternate study medication. No
      subject will be on D-serine for longer than 16 weeks. Admission criteria, Assessment
      Procedures, and Study Design will be the same across all sites. The procedures and timeline
      are shown in Table 1. The procedures and timeline are the same for the initial randomized 16
      week trial and the optional cross-over trial on the alternate study medication. If patient's
      opt for the 16 week treatment on the alternate medication, we will use their assessments from
      end of initial treatment as baseline for 16 week treatment on alternate medication. Subjects
      will be seen for two preliminary visits, then once in treatment, subjects will be seen weekly
      for the first 5 visits then biweekly thereafter. A safety blood and urine collection will be
      done on day 3 (3 days after the start of study medication). Vital signs and weight, blood
      draw and urine collection for safety measures, urine pregnancy test and urine for toxicology
      will be repeated throughout treatment. Adverse effects ratings and symptom assessments will
      be repeated at each visit. Neuropsychological assessment and optional &quot;Biomarker study&quot;
      visual, auditory and ERPs tasks will be administered during one of the two preliminary visits
      then again at study endpoint. Any patients who convert to frank psychosis will be
      referred/offered immediate treatment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">November 2012</completion_date>
  <primary_completion_date type="Actual">November 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Scale of Prodromal Symptoms (SOPS) Negative Scale</measure>
    <time_frame>16 weeks</time_frame>
    <description>The SOPS Negative symptom scale consists of six Negative Symptom items. Each item has a severity scale rating from 0 (Never, Absent) to 6 (Severe/Extreme). The severity of the prodromal state is judged according to the sum of the ratings from each of the SOPS items and ranges from 0 to 36.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Scale of Prodromal Symptoms (SOPS) Total</measure>
    <time_frame>16 weeks</time_frame>
    <description>The SOPS Total consists of five Positive Symptom items, six Negative Symptom items, four Disorganization Symptom items, and four General Symptom items. Each item has a severity scale rating from 0 (Never, Absent) to 6 (Severe/Extremeâ€”and Psychotic, for the positive items). The severity of the prodromal state is judged according to the sum of the ratings from each of the SOPS items and ranges from 0 to 114.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IL6 Levels</measure>
    <time_frame>16 weeks</time_frame>
    <description>Final IL6 levels (pg/ml) in available subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pittsburgh Sleep Quality Index Score</measure>
    <time_frame>16 weeks</time_frame>
    <description>The Pittsburgh Sleep Quality Index (PSQI) consists of 19 self-rated questions and five questions rated by the bed partner or roommate. The latter five questions are used for clinical information only, are not tabulated in the scoring of the PSQI. The 19 self-rated questions assess a wide variety of factors relating to sleep quality, including estimates of sleep duration and latency and of the frequency and severity of specific sleep-related problems. These I9 items are grouped into seven component scores, each weighted equally on a 0-3 scale. The seven component scores are then summed to yield a global PSQI score, which has a range of 0-21; higher scores</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Schizophrenia Prodrome</condition>
  <arm_group>
    <arm_group_label>D serine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>60 mg/kg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>D-serine</intervention_name>
    <description>60 mg/kg/day</description>
    <arm_group_label>D serine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Inert Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. treatment seeking subjects ages 13-35 who meet criteria for the schizophrenia prodrome
             (see criteria below) and who are able to give written informed assent or consent.

          2. Subjects must score at least 20 on the Scale of Prodromal Symptoms (SOPS) total score
             at visit -1.

          3. Patients may be receiving ongoing treatment with antipsychotic, antidepressant or
             anti-anxiety medications as prescribed by their treating physician, or may be
             medication free.

          4. Patients may enroll in the treatment phase only if they have been on fixed medication
             dosage for at least 4 weeks. If possible, medication will be held constant during
             course of study. Subjects will not be excluded or dropped from the study if they have
             a psychiatric diagnosis or must start a new medication unless the diagnosis is
             &quot;psychosis&quot;. Medication changes and increases or decreases in medication will be
             permitted at the discretion of the treating physician, and, if they occur, will be
             treated as secondary outcome measures.

        Exclusion criteria:

          1. inability to give informed assent or consent,

          2. history of psychosis (e.g. frank delusions, hallucinations, or thought disorder),

          3. psychotropic medication begun or dose adjusted within 4 weeks of visit 0,

          4. contraindication to study medication,

          5. inclusion symptoms better accounted for by comorbid diagnosis,

          6. treatment need for comorbid diagnosis outweighs that for prodromal symptoms,

          7. unstable medical illness,

          8. females who are of childbearing potential but are not taking adequate contraceptive
             precautions or who are pregnant or breast feeding,

          9. alcohol or drug abuse or dependence in the past three months,

         10. either of the following: Subjects with significant renal disease or estimated GFR
             below 60 (MDRD, http://www.kidney.org/professionals/kdoqi/gfr_calculator.cfm) will be
             excluded (see below for details). Any subject taking or unwilling to avoid other
             nephrotoxic agents during the course of the study (NSAIDS, ACE inhibitors, ARB's,
             calcineurin inhibitors, or aminoglycosides) will also be excluded. Therefore, patients
             will be asked during the study to take acetaminophen (e.g. if they have a headache)
             and to avoid taking ibuprofen.

        For adolescents (ages 13-17), more stringent renal exclusion criteria will be adhered to:

          1. estimated GFR is &lt; 89 cc/min/1.73 m2 as calculated by the Schwartz formula
             (http://www.kidney.org/professionals/kdoqi/gfr_calculatorPed.cfm),

          2. difference of â‰¥0.3mg/dl between the two baseline serum creatinine values,

          3. baseline proteinuria defined by a spot urine protein:creatinine of 0.2 or greater, or

          4. baseline glucosuria (the presence of glucosuria).

        Schizophrenia Prodrome Criteria:

        We will be enrolling both Attenuated Positive Syndrome (APS) [1], Genetic Familial Risk
        (GFR) [1] and Clinically High Risk Negative (CHR-) symptom prodromes to this study. A
        separate analysis will be done for the APS and CHR- patients.

          1. Attenuated Positive Syndrome: One or more of the 5 SOPS positive items scoring in the
             prodromal range (rating of 3-5) AND Symptoms beginning within the past year or
             increasing 1 or more points within the past year AND Symptoms occurring at least once
             per wk for last month.

          2. Genetic Familial Risk: First degree relative with history of any psychotic disorder OR
             Criteria for schizotypal personality disorder met in patient AND GAF drop of at least
             30% over the last month vs 1 year ago. In our experience, very few patients only meet
             criteria for this syndrome.

          3. CHR-: To make criteria, social isolation must be present along with either flat affect
             or impairment in the occupational role. Therefore to meet criteria for CHR-, Social
             Anhedonia (N1) has to be present at a score of 3 or above, and, in addition, one of
             the other two symptoms (N3 or N6) listed must also present at a minimum level of 3.
             Note: a score of &quot;6&quot; on these items is not considered exclusionary.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel C Javitt, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nathan Kline Institute for Psychiatric Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Yale University</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zucker Hillside Hospital</name>
      <address>
        <city>Glen Oaks</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York State Psychiatric Institute</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nathan Kline Institute</name>
      <address>
        <city>Orangeburg</city>
        <state>New York</state>
        <zip>10962</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Kantrowitz JT, Woods SW, Petkova E, Cornblatt B, Corcoran CM, Chen H, Silipo G, Javitt DC. D-serine for the treatment of negative symptoms in individuals at clinical high risk of schizophrenia: a pilot, double-blind, placebo-controlled, randomised parallel group mechanistic proof-of-concept trial. Lancet Psychiatry. 2015 May;2(5):403-412. doi: 10.1016/S2215-0366(15)00098-X. Epub 2015 Apr 28.</citation>
    <PMID>26360284</PMID>
  </results_reference>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 21, 2009</study_first_submitted>
  <study_first_submitted_qc>January 21, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 22, 2009</study_first_posted>
  <results_first_submitted>April 15, 2015</results_first_submitted>
  <results_first_submitted_qc>December 15, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 8, 2017</results_first_posted>
  <last_update_submitted>July 7, 2017</last_update_submitted>
  <last_update_submitted_qc>July 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>schizophrenia</keyword>
  <keyword>d-serine</keyword>
  <keyword>prodrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>D Serine</title>
          <description>60 mg/kg/day
D-serine: 60 mg/kg/day</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo: Inert Placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed Visit 4 (1st Efficacy Visit)</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Includes 35 subjects who received at least one post-baseline efficacy evaluation</population>
      <group_list>
        <group group_id="B1">
          <title>D Serine</title>
          <description>60 mg/kg/day
D-serine: 60 mg/kg/day</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo: Inert Placebo</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
            <count group_id="B2" value="20"/>
            <count group_id="B3" value="35"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20" spread="4.9"/>
                    <measurement group_id="B2" value="19" spread="3.5"/>
                    <measurement group_id="B3" value="19.5" spread="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>Scale of Prodromal Symptoms (SOPS) Total</title>
        <description>The SOPS Total consists of five Positive Symptom items, six Negative Symptom items, four Disorganization Symptom items, and four General Symptom items. Each item has a severity scale rating from 0 (Never, Absent) to 6 (Severe/Extremeâ€”and Psychotic, for the positive items). The severity of the prodromal state is judged according to the sum of the ratings from each of the SOPS items and ranges from 0 to 114.</description>
        <time_frame>16 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>D Serine</title>
            <description>60 mg/kg/day
D-serine: 60 mg/kg/day</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Inert Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Scale of Prodromal Symptoms (SOPS) Total</title>
          <description>The SOPS Total consists of five Positive Symptom items, six Negative Symptom items, four Disorganization Symptom items, and four General Symptom items. Each item has a severity scale rating from 0 (Never, Absent) to 6 (Severe/Extremeâ€”and Psychotic, for the positive items). The severity of the prodromal state is judged according to the sum of the ratings from each of the SOPS items and ranges from 0 to 114.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.9" spread="2.8"/>
                    <measurement group_id="O2" value="30.5" spread="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.07</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>cohen's d= 0.67</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>IL6 Levels</title>
        <description>Final IL6 levels (pg/ml) in available subjects</description>
        <time_frame>16 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>D Serine</title>
            <description>60 mg/kg/day
D-serine: 60 mg/kg/day</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Inert Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>IL6 Levels</title>
          <description>Final IL6 levels (pg/ml) in available subjects</description>
          <units>final IL6 level (pg/ml))</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".49" spread=".25"/>
                    <measurement group_id="O2" value=".79" spread=".52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.056</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>cohen's d=0.84</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Scale of Prodromal Symptoms (SOPS) Negative Scale</title>
        <description>The SOPS Negative symptom scale consists of six Negative Symptom items. Each item has a severity scale rating from 0 (Never, Absent) to 6 (Severe/Extreme). The severity of the prodromal state is judged according to the sum of the ratings from each of the SOPS items and ranges from 0 to 36.</description>
        <time_frame>16 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>D Serine</title>
            <description>60 mg/kg/day
D-serine: 60 mg/kg/day</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Inert Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Scale of Prodromal Symptoms (SOPS) Negative Scale</title>
          <description>The SOPS Negative symptom scale consists of six Negative Symptom items. Each item has a severity scale rating from 0 (Never, Absent) to 6 (Severe/Extreme). The severity of the prodromal state is judged according to the sum of the ratings from each of the SOPS items and ranges from 0 to 36.</description>
          <units>SOPS negative final score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.6" spread="1.4"/>
                    <measurement group_id="O2" value="11.3" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.03</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Cohen's d=0.68</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pittsburgh Sleep Quality Index Score</title>
        <description>The Pittsburgh Sleep Quality Index (PSQI) consists of 19 self-rated questions and five questions rated by the bed partner or roommate. The latter five questions are used for clinical information only, are not tabulated in the scoring of the PSQI. The 19 self-rated questions assess a wide variety of factors relating to sleep quality, including estimates of sleep duration and latency and of the frequency and severity of specific sleep-related problems. These I9 items are grouped into seven component scores, each weighted equally on a 0-3 scale. The seven component scores are then summed to yield a global PSQI score, which has a range of 0-21; higher scores</description>
        <time_frame>16 weeks</time_frame>
        <population>Completers at NYSPI and NKI sites</population>
        <group_list>
          <group group_id="O1">
            <title>D Serine</title>
            <description>60 mg/kg/day
D-serine: 60 mg/kg/day</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Inert Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Pittsburgh Sleep Quality Index Score</title>
          <description>The Pittsburgh Sleep Quality Index (PSQI) consists of 19 self-rated questions and five questions rated by the bed partner or roommate. The latter five questions are used for clinical information only, are not tabulated in the scoring of the PSQI. The 19 self-rated questions assess a wide variety of factors relating to sleep quality, including estimates of sleep duration and latency and of the frequency and severity of specific sleep-related problems. These I9 items are grouped into seven component scores, each weighted equally on a 0-3 scale. The seven component scores are then summed to yield a global PSQI score, which has a range of 0-21; higher scores</description>
          <population>Completers at NYSPI and NKI sites</population>
          <units>final score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" spread="2.9"/>
                    <measurement group_id="O2" value="7.7" spread="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.12</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>cohen's d=0.93</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>D Serine</title>
          <description>60 mg/kg/day
D-serine: 60 mg/kg/day</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo: Inert Placebo</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>suicidal thoughts-hospitalization</sub_title>
                <description>patient remained in study</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Out of range renal values</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Daniel Javitt MD, PhD</name_or_title>
      <organization>Nathan Kline Institute</organization>
      <phone>845-398-6534</phone>
      <email>javitt@nki.rfmh.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

